Biora Therapeutics Inc
NASDAQ:BIOR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.22
0.627
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Operating Margin
Biora Therapeutics Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
994.4k USD |
-6 824%
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
98.8B USD |
3%
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
62.3B EUR |
4%
|
|
| US |
|
Cigna Corp
NYSE:CI
|
73B USD |
4%
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
27B EUR |
10%
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.5B EUR |
7%
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
20.9B USD |
10%
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
19.6B USD |
15%
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.7B EUR |
7%
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
12.1B USD |
-48%
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
8.2B USD |
15%
|
Biora Therapeutics Inc
Glance View
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Biora Therapeutics Inc's most recent financial statements, the company has Operating Margin of -6 824.3%.